174 related articles for article (PubMed ID: 36512266)
1. Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Syal G; Melmed GY; Almario CV; Spiegel BMR
Dig Dis Sci; 2023 Feb; 68(2):404-413. PubMed ID: 36512266
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
Chande N; Patton PH; Tsoulis DJ; Thomas BS; MacDonald JK
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD000067. PubMed ID: 26517527
[TBL] [Abstract][Full Text] [Related]
5. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
6. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
[TBL] [Abstract][Full Text] [Related]
7. The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.
Bolin K; Hertervig E; Louis E
J Crohns Colitis; 2019 Sep; 13(10):1323-1333. PubMed ID: 30893421
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Townsend CM; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission.
Jeong TJ; Kim ES; Kwon Y; Kim S; Seo SW; Choe YH; Kim MJ
Sci Rep; 2022 Jan; 12(1):507. PubMed ID: 35017546
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Tsoulis DJ; MacDonald JK
Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
[TBL] [Abstract][Full Text] [Related]
13. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
Kang B; Choi SY; Choi YO; Kim MJ; Kim K; Lee JH; Choe YH
J Crohns Colitis; 2018 May; 12(6):644-652. PubMed ID: 29474531
[TBL] [Abstract][Full Text] [Related]
14. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA; Jongsma MME; Hoeven BM; Cozijnsen MA; van Pieterson M; de Meij TGJ; Norbruis OF; Groeneweg M; Wolters VM; van Wering H; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg S; Rizopoulos D; Poley MJ; Escher JC; de Ridder L
Aliment Pharmacol Ther; 2024 Jun; 59(12):1510-1520. PubMed ID: 38644588
[TBL] [Abstract][Full Text] [Related]
18. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
Magro F; Santos-Antunes J; Vilas-Boas F; Rodrigues-Pinto E; Coelho R; Ribeiro OS; Lopes S; Macedo G
J Crohns Colitis; 2014 Jul; 8(7):617-25. PubMed ID: 24332869
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
20. Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
Alizadeh ER; Dervieux T; Vermeire S; Dubinsky M; D'Haens G; Laharie D; Shim A; Vaughn BP
Pharmacotherapy; 2024 Apr; 44(4):331-342. PubMed ID: 38576238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
